MARKET

ZOM

ZOM

Zomedica Corp
AMEX

Real-time Quotes | Nasdaq Last Sale

0.8500
-0.1251
-12.83%
After Hours: 0.8455 -0.0045 -0.53% 19:59 04/16 EDT
OPEN
0.9081
PREV CLOSE
0.9751
HIGH
0.9405
LOW
0.8300
VOLUME
80.76M
TURNOVER
--
52 WEEK HIGH
2.910
52 WEEK LOW
0.0628
MARKET CAP
805.20M
P/E (TTM)
-13.7987
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Sundial Growers, Zomedica, Naked Brand, Meten Edtechx Education, or BioNano Genomics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ZOM, NAKD, METX, and BNGO.
PR Newswire - PRF · 1d ago
Thinking about buying stock in Sundial Growers, Zomedica, Naked Brand, Taoping, or Assertio?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ZOM, NAKD, TAOP, and ASRT.
PR Newswire - PRF · 2d ago
Sector Update: Health Care Stocks Keep Upbeat Momentum into Late Trade
MT Newswires · 2d ago
Ardelyx, Liquidia leads healthcare gainers; Zomedica, Affimed among major losers
Gainers: Ardelyx (ARDX) +13%, Liquidia (LQDA) +9%, PPD (PPD) +7%, Inovio Pharmaceuticals (INO) +6%, BiomX (PHGE) +6%.Losers: Zomedica (ZOM) -12%, Affimed (AFMD) -10%, Aesthetic Medical International (AIH) -7%, Galectin Therapeutics (GALT) -8%, Ekso Bionics...
Seekingalpha · 2d ago
Sector Update: Health Care Stocks Extending Markets-Leading Rise
MT Newswires · 2d ago
Zomedica to build direct sales force for TRUFORMA platform
Zomedica (ZOM) shares slide more than 6% during premarket trading after the company announced that it intends to expand its direct sales organization while phasing out its distributor-based sales efforts."As TRUFORMA’s market presence grew,
Seekingalpha · 2d ago
Virgin Galactic Holdings, Zomedica among premarket losers' pack
Global Self Storage (SELF) -7%.Virgin Galactic Holdings (SPCE) -5% after Richard Branson sells off $150M stake.Zomedica (ZOM) -5% after proposes to build direct sales force for TRUFORMA platform.
Seekingalpha · 2d ago
BRIEF-Zomedica To Build Direct Sales Force For Truforma Platform
reuters.com · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZOM. Analyze the recent business situations of Zomedica Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZOM stock price target is 1.200 with a high estimate of 1.200 and a low estimate of 1.200.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 14.30M
% Owned: 1.51%
Shares Outstanding: 947.30M
TypeInstitutionsShares
Increased
10
618.54K
New
6
747.38K
Decreased
7
136.68K
Sold Out
15
2.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Director
Jeffrey Rowe
President/Chief Operating Officer
Stephanie Morley
Chief Executive Officer/Director
Robert Cohen
Chief Financial Officer/Secretary
Ann Cotter
Executive Director/Other
William MacArthur
Other
Andrea Eberle
Other
Angy Guerrant
Other
Bruk Herbst
Other
Angie Moricz
Director
Christopher Wolfenberg
Independent Director
Tom Robitaille
Independent Director
Jane Eagleson
Independent Director
Jeff Rowe
Independent Director
Christopher MacLeod
Independent Director
Johnny Powers
Independent Director
Thomas Robitaille
Independent Director
Rodney Williams
No Data
About ZOM
Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.

Webull offers kinds of Zomedica Corp stock information, including AMEX:ZOM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZOM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZOM stock methods without spending real money on the virtual paper trading platform.